This is a working overview of NAD+, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-04 and is reviewed periodically as new material appears.
The biologically relevant form of NMN is generally the beta anomer, which is recognized by NMN adenylyltransferases. NMN is polar and water soluble, and it does not readily diffuse across lipid membranes without assistance. Whether intact NMN enters cells through a specific transporter remains an open question; some studies propose solute carrier family members, while other work favors extracellular dephosphorylation to nicotinamide riboside followed by uptake. This transport and compartmentalization debate affects how researchers interpret oral administration studies. The distinction between intracellular synthesis and extracellular delivery is central to current discussion.
Terminology around NMN can be confusing because several related compounds share the vitamin B3 family. Nicotinamide riboside is a nucleoside, whereas NMN is a nucleotide with a phosphate group, and NAD+ is a dinucleotide coenzyme rather than a simple precursor. Niacin and nicotinamide are also NAD+ precursors but follow different metabolic entry points. In commercial and scientific writing, NMN usually refers to beta-nicotinamide mononucleotide unless another form is specified. Consistent nomenclature helps distinguish chemical identity from proposed biological effects.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
In the canonical salvage pathway, nicotinamide phosphoribosyltransferase, known as NAMPT, transfers a phosphoribosyl group to nicotinamide and releases NMN. A second enzyme, NMN adenylyltransferase, then attaches an adenylyl group to NMN to form NAD+. Alternative routes exist, including a pathway that uses nicotinamide riboside and its phosphorylated forms. The relative contribution of extracellular NMN to intracellular NAD+ pools remains an area of active investigation, and the roles of specific transporters and enzymes are not completely defined.
| Property | Value | Notes |
|---|---|---|
| Systematic class | Pyridine nucleotide | Contains nicotinamide, ribose, and phosphate |
| Common form | beta-NMN | Anomeric configuration relevant to enzyme recognition |
| Molecular formula | C11H15N2O8P | As the free acid |
| Molar mass | 334.22 g/mol | Calculated for the free acid |
| CAS Registry Number | 1094-61-7 | Commonly associated with beta-D-NMN |
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
Research on NMN includes cell studies, animal experiments, and a growing number of human trials. Many early findings come from mice, where changes in NAD+ levels and metabolic markers have been reported. Human data are more limited, and questions remain about effective routes of administration, tissue distribution, and long-term effects. Some trials measure NAD+ in blood or tissue, while others assess physical function or metabolic outcomes. Regulatory status differs between countries, and NMN is not universally approved as a dietary supplement or therapeutic agent.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms. Its structure consists of a nicotinamide group linked to a ribose sugar that carries a phosphate group. NMN is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide, or NAD+, a coenzyme involved in many metabolic reactions. The abbreviation usually refers to the beta anomer, though related forms can exist. In scientific literature, NMN is distinct from nicotinamide riboside, another NAD+ precursor.
In the NAD+ salvage pathway, the enzyme NAMPT converts nicotinamide and a phosphate-donor molecule into NMN. A second enzyme, NMNAT, then converts NMN into NAD+. Nicotinamide riboside can also enter this route after being converted to NMN by nicotinamide riboside kinases. Because NMN sits at a junction between precursor uptake and NAD+ formation, its cellular concentration is tightly linked to enzyme activity and tissue type. NAD+ participates in redox reactions, signaling, and DNA repair, and its levels decline with age in some animal models, though human evidence remains more limited and context-dependent.
Another strategy for site-specific amine conjugation to proteins is to replace lysine residues with arginine residues (LDVs). If all lysines are depleted then the only remaining free amine is at the amino terminus (N-terminus) of the protein. In the case where the protein is an antibody Fc domain, a recombinant LDV Fc can still be purified using protein A. LDV Fc proteins fused with short peptide targeting sequences can be used to deliver conjugated payloads, including nanoparticles, to specific cell surface proteins. The majority of ADCs under development or in clinical trials are for oncological and hematological indications. This is primarily driven by the inventory of monoclonal antibodies, which target various types of cancer. However, some developers are looking to expand the application to other important disease areas.
The most abundant thorium minerals are thorianite (ThO2), thorite (ThSiO4) and monazite, ((Th,Ca,Ce)PO4). Most thorium minerals contain uranium and vice versa; and they all have significant fraction of lanthanides. Rich deposits of thorium minerals are located in the United States (440,000 tonnes), Australia and India (~300,000 tonnes each) and Canada (~100,000 tonnes). The abundance of actinium in the Earth's crust is only about 5×10−15%. Actinium is mostly present in uranium-containing, but also in other minerals, though in much smaller quantities. The content of actinium in most natural objects corresponds to the isotopic equilibrium of parent isotope 235U, and it is not affected by the weak Ac migration. Protactinium is more abundant (10−12%) in the Earth's crust than actinium. It was discovered in uranium ore in 1913 by Fajans and Göhring. As actinium, the distribution of protactinium follows that of 235U. The half-life of the longest-lived isotope of neptunium, 237Np, is negligible compared to the age of the Earth. Thus neptunium is present in nature in negligible amounts produced as intermediate decay products of other isotopes. Traces of plutonium in uranium minerals were first found in 1942, and the more systematic results on 239Pu are summarized in the table (no other plutonium isotopes could be detected in those samples). The upper limit of abundance of the longest-living isotope of plutonium, 244Pu, is 3×10−20%. Plutonium could not be detected in samples of lunar soil. Owing to its scarcity in nature, most plutonium is produced synthetically.
== Medical uses == Glibenclamide is used to lower the blood sugar level in patients with type 2 diabetes mellitus, which is not controlled by diet and exercise alone. It is not as good as either metformin or insulin in those who have gestational diabetes.
Sources: en.wikipedia.org
The Bloomberg tablets are a collection of 405 preserved wooden tablets that were found at the site of the Bloomberg building in the financial district of London. Excavations of the site took place between 2010 and 2013, after which the current Bloomberg building was constructed on the site of the archaeological dig. The tablets are the earliest written documents found in Britain, dating from 50 to 80 AD in the early Roman period. These tablets predate the Vindolanda tablets, which were previously the earliest writing examples found in Britain, dating to 100 AD or later.
== Personal life == Cross is a former police officer and English teacher. She speaks English, French, Russian and Japanese. This is due to her time living in France, Russia and Japan. In 2014, she published her first book, Devil and Disciple – The Temptation. Her sponsors are CNP Professional, Melanotan Europe, and Powerzone Gym Equipment. She runs her own community gym. She is also a hardcore pornographic performer.
That's why they're stuck where they are.'" Kingsolver said that she resented all parts of Hillbilly Elegy, feeling that Vance was not from Appalachia and did not understand the community. Following Hillbilly Elegy, a surge in publishing from marginalized communities in Appalachia began as an effort to counter stereotypes of the region by sharing a wider range of more nuanced stories. They were motivated by broadening narratives about Appalachia to counter longstanding national stereotypes about the region, which they attributed both to Hillbilly Elegy's recent popularity and widespread biases. Haymarket Books, Hub City Press, West Virginia University Press, and University Press of Kentucky led concerted efforts to publish more diverse writing about the region. University Press of Kentucky's Appalachian Futures series explicitly sought to give "voice to Black, Native, Latinx, Asian, Queer, and other nonwhite or ignored identities within the Appalachian region". Its first book, Tar Hollow Trans, was published in 2023.
Sources: en.wikipedia.org
The adipokines, or adipocytokines (Greek adipo-, fat; cytos-, cell; and -kinos, movement) are cytokines (cell signaling proteins) secreted by adipose tissue. Some contribute to an obesity-related low-grade state of inflammation or to the development of metabolic syndrome, a constellation of diseases including, but not limited to, type 2 diabetes, cardiovascular disease and atherosclerosis. The first adipokine to be discovered was leptin in 1994. Since that time, hundreds of adipokines have been discovered. Members include: Leptin Adiponectin Apelin chemerin interleukin-6 (IL-6) monocyte chemotactic protein-1 (MCP-1) plasminogen activator inhibitor-1 (PAI-1) retinol binding protein 4 (RBP4) tumor necrosis factor visfatin omentin vaspin (SERPINA12) progranulin CTRP-4 Interleukin 8 (IL-8), interleukin 10 (IL-10), interferon gamma (IFN-γ) and inducible protein 10 (IP-10 or CXCL10) have been shown to be associated with excessive body weight. Adipose tissue Hepatokines Myokines Adipokines at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
The iodine pit, also called the iodine hole or xenon pit, is a temporary disabling of a nuclear reactor due to the buildup of short-lived neutron poisons in the reactor core. The main isotope responsible is 135Xe, mainly produced by beta decay of 135I. 135I is a weak neutron absorber, while 135Xe is the strongest known neutron absorber. When 135Xe builds up in the fuel rods of a reactor, it significantly lowers their reactivity, by absorbing a significant amount of the neutrons that provide the nuclear reaction. The presence of 135I and 135Xe in the reactor is one of the main reasons for its power fluctuations in reaction to change of control rod positions. The buildup of short-lived fission products acting as nuclear poisons is called reactor poisoning, or xenon poisoning. The buildup of stable or long-lived neutron poisons is called reactor slagging.
==== New Zealand ==== In 2017, the New Zealand government made changes to the regulations so that restrictions would be removed, which meant a doctor was able to prescribe cannabidiol to patients. The passing of the Misuse of Drugs (Medicinal Cannabis) Amendment Act in December 2018 means cannabidiol is no longer a controlled drug in New Zealand, but is a prescription medicine under the Medicines Act, with the restriction that "the tetrahydrocannabinols (THCs) and specified substances within the product must not exceed 2 percent of the total CBD, tetrahydrocannabinol (THC) and other specified substances."
==== Eulipotyphlan research ==== Valenzuela et al. (2026) study the evolution of the postcranial skeleton in the lineage of Nesiotites from the Pliocene to the Holocene, reporting that members of the studied lineage underwent a size shift throughout their evolutionary history but retained adaptations to terrestrial generalist locomotion. A study on the composition and evolution of Miocene erinaceid assemblages from the Daroca-Calamocha area (Spain) is published by Cailleux et al. (2026). Cailleux (2026) identifies common dental pathologies in the fossil material of Galerix stehlini from the Miocene strata from La Grive-Saint-Alban (France), and interprets their recurrence as possibly linked to small population size linked to habitat fragmentation.
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide intermediate in NAD+ biosynthesis.
NMN is a direct precursor in the salvage pathway that produces NAD+. Enzymes called NMN adenylyltransferases convert NMN into NAD+, a coenzyme involved in redox reactions and signaling.
No. Nicotinamide riboside is a related compound that lacks the phosphate group present in NMN. Both can influence NAD+ pathways, but their structures, transport, and metabolism differ.
NMN is nicotinamide mononucleotide, a nucleotide intermediate in NAD+ biosynthesis. It occurs naturally in cells and is also produced commercially as a supplement ingredient.